GlaxoSmithKline Plc has declared an unchanged dividend of 19 pence per share for the third quarter after delivering increases in both turnover and operating profit. Earnings per share at constant exchange rates are expected to decline by 2% to 4% for the year as a whole – an improvement over the company’s earlier forecast of a decline in the mid-to-high single digit range. The earnings per share forecast excludes impairments and the amortisation of intangible assets.
